About CellPoint
CellPoint is a company based in Leiden (Netherlands) founded in 2018 by Maarten Zandvliet was acquired by Galapagos in June 2022. CellPoint offers products and services including xCellit workflow system and Decentralized manufacturing platform. CellPoint operates in a competitive market with competitors including Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
- Headquarter Leiden, Netherlands
- Founders Maarten Zandvliet
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Galapagos Nv
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of CellPoint
CellPoint offers a comprehensive portfolio of products and services, including xCellit workflow system and Decentralized manufacturing platform.
Manages end-to-end workflow for cell therapy monitoring and operations.
Automates cell therapy production using closed systems for efficient treatment.
Funding Insights of CellPoint
Detailed funding history for CellPoint
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in CellPoint
CellPoint has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include GLPG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Small molecule drugs for immunology and oncology are developed.
|
Locked | Locked | Locked |
Investor details for CellPoint
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by CellPoint
Investment portfolio details for CellPoint
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - CellPoint
Detailed financials for CellPoint
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellpoint Comparisons
Peer comparison for CellPoint
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of CellPoint
CellPoint operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Poseida Therapeutics, Juno Therapeutics, TScan Therapeutics, Lyell Immunopharma and Autolus, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
T cell-based treatments for immunological and oncological disorders are developed.
|
|
| Locked | Locked | Locked |
CAR-T and TIL immunotherapies for solid tumors are developed.
|
|
| Locked | Locked | Locked |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases.
|
|
| Locked | Locked | Locked |
Developer of CAAR T cells for B cell-mediated autoimmune diseases
|
Detailed competitors of CellPoint
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellpoint
Complete news archive for CellPoint
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about CellPoint
CellPoint was founded in 2018.
CellPoint is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
CellPoint was founded in 2018 in Leiden, Netherlands, within the biotechnology sector focused on oncology. CAR-T cell-based therapeutics are developed to treat hematological malignancies, including acute lymphocytic leukemia, chronic lymphocytic leukemia, acute myeloid leukemia, and Hodgkins and non-Hodgkins lymphomas. Patient immune cells are retargeted at the point-of-care for personalized treatment. Key pipelines encompass CD-19 CAR-T in phase 2 clinical trials and BCMA CAR-T in the preclinical stage, among others.
CellPoint's top competitors include Juno Therapeutics, Lyell Immunopharma and Immatics.
CellPoint offers xCellit workflow system and Decentralized manufacturing platform.
CellPoint has 1 investor. Key investors include GLPG.